Applied Therapeutics Taps Chuck Silberstein as Chief Financial Officer

Applied Therapeutics (NASDAQ: [[ticker:APLT]]) appointed Charles “Chuck” Silberstein as its chief financial officer and head of business development. He succeeds CFO Mark Vignola, who joined Applied as CFO in April 2019 and is now moving on “to pursue new business opportunities.”

Silberstein was most recently senior vice president of corporate business development at Allergan, whose acquisition by AbbVie (NYSE: [[ticker:ABBV]]) closed this month. Prior roles include portfolio manager and equity healthcare analyst at The Boston Company Asset Management and Goldman Sachs Asset Management and senior healthcare equity analyst at JP Morgan Asset Management. New York-based Applied’s lead drug candidate, AT-007, is an investigational treatment for patients with the rare pediatric metabolic disease galactosemia.

Author: Sarah de Crescenzo

Sarah is Xconomy's San Diego-based editor. Prior to joining the team in 2018, she wrote about startups, tech and finance at the San Diego Business Journal. Her decade of full-time news experience includes coverage of subjects including campaign finance, crime and courts as a reporter and editor at outlets throughout California, including the Orange County Register. She earned a bachelor's degree in English Literature at UC San Diego, where she wrote for the student newspaper and played collegiate lacrosse. In 2019, she earned an MBA at UC Irvine. View all posts by Sarah de Crescenzo